Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
- 31 December 2012
- journal article
- Published by Elsevier BV in Value in Health
- Vol. 15 (8), 1162-1171
- https://doi.org/10.1016/j.jval.2012.05.006
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Cost Effectiveness of PharmacogenomicsPharmacoEconomics, 2010
- Comparative Effectiveness, Personalized Medicine and InnovationPharmacoEconomics, 2010
- Comparative Effectiveness Research and Personalized MedicinePharmacoEconomics, 2010
- Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?PharmacoEconomics, 2010
- Economic Opportunities and Challenges for PharmacogenomicsAnnual Review of Pharmacology and Toxicology, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2009
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabThe New England Journal of Medicine, 2009
- Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analysesPersonalized Medicine, 2009
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Economic and Developmental Considerations for Pharmacogenomic TechnologyPharmacoEconomics, 2006